UCB SA (UCBJF)
USD 150.7
(-5.46%)
USD 150.7
(-5.46%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 604 Million EUR | -52.31% |
| 2022 | 585 Million EUR | -54.44% |
| 2021 | 1.28 Billion EUR | 32.23% |
| 2020 | 971 Million EUR | -9.08% |
| 2019 | 1.06 Billion EUR | -3.7% |
| 2018 | 1.1 Billion EUR | 2.02% |
| 2017 | 1.08 Billion EUR | 24.09% |
| 2016 | 876 Million EUR | 67.82% |
| 2015 | 522 Million EUR | 91.21% |
| 2014 | 273 Million EUR | -32.26% |
| 2013 | 403 Million EUR | 3.6% |
| 2012 | 389 Million EUR | 13.08% |
| 2011 | 344 Million EUR | 68.63% |
| 2010 | 204 Million EUR | -75.63% |
| 2009 | 837 Million EUR | 640.71% |
| 2008 | 113 Million EUR | -67.15% |
| 2007 | 344 Million EUR | -39.75% |
| 2006 | 571 Million EUR | 56.87% |
| 2005 | 364 Million EUR | -24.8% |
| 2004 | 484.01 Million EUR | -0.52% |
| 2003 | 486.54 Million EUR | -3.16% |
| 2002 | 502.39 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 163 Million EUR | -7.39% |
| 2024 Q2 | 161.5 Million EUR | -0.92% |
| 2023 Q3 | 82.5 Million EUR | -82.78% |
| 2023 Q1 | 206.5 Million EUR | 75.0% |
| 2023 FY | 279 Million EUR | -52.31% |
| 2023 Q4 | 176 Million EUR | 113.33% |
| 2023 Q2 | 479 Million EUR | 131.96% |
| 2022 Q4 | 118 Million EUR | 0.0% |
| 2022 Q2 | 546 Million EUR | 133.33% |
| 2022 Q1 | 234 Million EUR | -61.83% |
| 2022 FY | 585 Million EUR | -54.44% |
| 2021 FY | 1.28 Billion EUR | 32.23% |
| 2021 Q4 | 613 Million EUR | 94.29% |
| 2021 Q3 | 315.5 Million EUR | -54.21% |
| 2021 Q2 | 689 Million EUR | 101.76% |
| 2021 Q1 | 341.5 Million EUR | -27.49% |
| 2020 Q2 | 607 Million EUR | 97.72% |
| 2020 Q4 | 471 Million EUR | 123.22% |
| 2020 Q1 | 307 Million EUR | -41.97% |
| 2020 FY | 971 Million EUR | -9.08% |
| 2020 Q3 | 211 Million EUR | -65.24% |
| 2019 Q4 | 529 Million EUR | 0.0% |
| 2019 FY | 1.06 Billion EUR | -3.7% |
| 2019 Q1 | 283 Million EUR | 0.0% |
| 2019 Q2 | 555 Million EUR | 96.11% |
| 2018 Q2 | 328.5 Million EUR | 0.0% |
| 2018 FY | 1.1 Billion EUR | 2.02% |
| 2018 Q1 | 328.5 Million EUR | 28.32% |
| 2017 FY | 1.08 Billion EUR | 24.09% |
| 2017 Q2 | 281.5 Million EUR | 0.0% |
| 2017 Q1 | 281.5 Million EUR | 54.67% |
| 2017 Q4 | 256 Million EUR | 0.0% |
| 2017 Q3 | 256 Million EUR | -9.06% |
| 2016 Q1 | 216 Million EUR | 68.09% |
| 2016 FY | 876 Million EUR | 67.82% |
| 2016 Q3 | 182 Million EUR | -15.74% |
| 2016 Q4 | 182 Million EUR | 0.0% |
| 2016 Q2 | 216 Million EUR | 0.0% |
| 2015 Q4 | 128.5 Million EUR | 0.0% |
| 2015 Q1 | 160 Million EUR | 75.82% |
| 2015 Q2 | 160 Million EUR | 0.0% |
| 2015 Q3 | 128.5 Million EUR | -19.69% |
| 2015 FY | 522 Million EUR | 91.21% |
| 2014 Q1 | 99 Million EUR | 45.59% |
| 2014 Q3 | 91 Million EUR | -8.08% |
| 2014 Q2 | 99 Million EUR | 0.0% |
| 2014 Q4 | 91 Million EUR | 0.0% |
| 2014 FY | 273 Million EUR | -32.26% |
| 2013 Q3 | 68 Million EUR | -20.0% |
| 2013 Q1 | 85 Million EUR | 0.0% |
| 2013 FY | 403 Million EUR | 3.6% |
| 2013 Q4 | 68 Million EUR | 0.0% |
| 2013 Q2 | 85 Million EUR | 0.0% |
| 2012 FY | 389 Million EUR | 13.08% |
| 2011 FY | 344 Million EUR | 68.63% |
| 2010 FY | 204 Million EUR | -75.63% |
| 2009 FY | 837 Million EUR | 640.71% |
| 2008 FY | 113 Million EUR | -67.15% |
| 2007 FY | 344 Million EUR | -39.75% |
| 2006 FY | 571 Million EUR | 56.87% |
| 2005 FY | 364 Million EUR | -24.8% |
| 2004 FY | 484.01 Million EUR | -0.52% |
| 2003 FY | 486.54 Million EUR | -3.16% |
| 2002 FY | 502.39 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Qrons Inc. | -643.67 Thousand USD | 93935.884% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 1188.131% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 48189.172% |
| Adynxx, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | -637.918% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 145474.375% |
| BioStem Technologies, Inc. | -7.77 Million USD | 7864.525% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 3484.322% |
| Skye Bioscience, Inc. | -13.67 Million USD | 4517.853% |
| Rebus Holdings, Inc. | -664 Thousand USD | 91063.855% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 12073.477% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 45328.844% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 155142.739% |
| Nascent Biotech, Inc. | -2.22 Million USD | 27186.672% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 3905.986% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 941.39% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -12189.384% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 230875.697% |
| SQZ Biotechnologies Company | -75.82 Million USD | 896.571% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 21289.213% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 39421.662% |
| Mesoblast Limited | -84.14 Million USD | 817.791% |
| Marizyme, Inc. | -34.08 Million USD | 1871.962% |
| Genus plc | 6.4 Million USD | -9337.5% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -6099.667% |
| Pharming Group N.V. | -4.87 Million USD | 12478.206% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 30505.557% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 64950.008% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 7333.533% |
| ContraFect Corporation | -56.88 Million USD | 1161.717% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 13360.951% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 43181.589% |
| IMV Inc. | -38.67 Million USD | 1661.873% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 22056.938% |
| MultiCell Technologies, Inc. | -722.81 USD | 83562861.998% |
| ONE Bio Corp. | 13.68 Million USD | -4314.705% |
| Accustem Sciences Inc. | -3.74 Million USD | 16222.062% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 1123.902% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 125135.71% |
| Q BioMed Inc. | -3.44 Million USD | 17629.522% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -16962.147% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 23087.438% |
| Biomind Labs Inc. | -1 Million USD | 59925.496% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 1198.734% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 20918.613% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 9185.419% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 32497.003% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 2016659.829% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 31353.072% |
| GB Sciences, Inc. | -1.42 Million USD | 42619.97% |
| Alpha Cognition Inc. | -9.7 Million USD | 6323.211% |
| HST Global, Inc. | -140.9 Thousand USD | 428751.522% |
| CSL Limited | 3.7 Billion USD | 83.684% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 53793.375% |
| Halberd Corporation | -75.05 Thousand USD | 804896.802% |
| Enzolytics Inc. | -2.14 Million USD | 28208.712% |
| Agentix Corp. | -1.37 Million USD | 44131.154% |
| Resverlogix Corp. | -12.74 Million USD | 4837.626% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 19164.008% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -425.04 Million USD | 242.101% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 57954.406% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 20788.871% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 38343.46% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 17838.729% |
| AVAX Technologies, Inc. | 6.69 Million USD | -8924.516% |
| Zenith Capital Corp. | -8.94 Million USD | 6853.886% |
| Genscript Biotech Corporation | -415.79 Million USD | 245.265% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 3467179.961% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 24699.675% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 352266.999% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 30228.34% |
| Kadimastem Ltd | -3.04 Million USD | 19966.787% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 61478.808% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 332909.874% |
| LadRx Corporation | -3.82 Million USD | 15896.524% |
| Cell Source, Inc. | -4.32 Million USD | 14064.201% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 88024.885% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 88024.885% |
| NovAccess Global Inc. | -2.46 Million USD | 24585.56% |
| Affymax, Inc. | -15.04 Million USD | 4114.356% |
| Itoco Inc. | -919.14 Thousand USD | 65813.602% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 14350.614% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 54076.765% |
| Mobile Lads Corp. | -554.55 Thousand USD | 109017.14% |
| CytoDyn Inc. | -18.05 Million USD | 3444.778% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 2399782.161% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 274548.15% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 107055.091% |
| SYBLEU INC | -149.18 Thousand USD | 404980.011% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 33354.052% |
| International Stem Cell Corporation | -663 Thousand USD | 91201.056% |
| Bioxytran, Inc. | -3.82 Million USD | 15910.91% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 1147516.413% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 2969618.191% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 1765.472% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 37430.037% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 82183.619% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 19514.979% |
| Neutra Corp. | -229.48 Thousand USD | 263296.883% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 3543.754% |
| PureTech Health plc | -146.19 Million USD | 513.136% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 2910.463% |
| IXICO plc | -1.43 Million USD | 42132.011% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 6463.924% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 595.87% |
| CSL Limited | 3.81 Billion USD | 84.155% |
| Cellectis S.A. | -108.85 Million USD | 654.855% |